Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Background This phase I study evaluated the safety and tolerability, pharmacokinetics and pharmacodynamics, immunogenicity, and antitumor activity of pembrolizumab in Japanese patients with advanced solid tumors. Methods Following an initial dose and a 28-day rest (cycle 1), pembrolizumab was admini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Shimizu, Toshio, Seto, Takashi, Hirai, Fumihiko, Takenoyama, Mitsuhiro, Nosaki, Kaname, Tsurutani, Junji, Kaneda, Hiroyasu, Iwasa, Tsutomu, Kawakami, Hisato, Noguchi, Kazuo, Shimamoto, Takashi, Nakagawa, Kazuhiko
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2016
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4859860/
https://ncbi.nlm.nih.gov/pubmed/27000274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0347-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados